top of page
Fig 1_mutantpos.tif


The pathophysiological functions of the signaling molecules matrix metalloproteinase-14 (MMP-14) and integrin αvβ3 in various types of cancer are believed to derive from their collaborative activity in promoting invasion, metastasis, and angiogenesis. To address the lack of multitarget inhibitors, we establish a combinatorial approach that is based on flow cytometry screening of a yeast-displayed N-TIMP2 (N-terminal domain variant of tissue inhibitor of metalloproteinase-2) mutant library. On the basis of this screening, we identify protein monomers and generate protein heterodimers that contain monovalent and bivalent binding epitopes to MMP-14 and integrin αvβ3.


Strategy for screening the N-TIMP2RGD library. (A) YSD system. N-TIMP2RGD proteins were displayed on yeast. Expression of the N-TIMP2RGD proteins was detected by targeting the C-Myc epitope tag, expressed at the C-terminal of the protein, with an antibody labeled with phycoerythrin (PE), and binding to integrin αvβ3 was detected by FITC staining. (B) Flow cytometry analysis of the sorted library tested against 50 nM of integrin αvβ3. In the expression sort (ES), the entire N-TIMP2RGD protein-expressing cell population was sorted (black gate). In sort 1 (S1), the yeast cell population binding to integrin αvβ3 was collected (black gate). In sort 2 (S2) to sort 5 (S5), the integrin αvβ3 high affinity population was collected (black gate). The population binding integrin αvβ3 was enriched as the sorting progressed from S2 to S5. (C) N-TIMP2 protein variants. N-TIMP2WT,RGD is the bi-specific protein isolated after sort 5. N-TIMP25M,RGD is N-TIMP2WT,RGD with 5 mutations (5M); this mutant showed improved binding to MMP-14 (39). N-TIMP2HD is a heterodimer composed of N-TIMP25M and N-TIMP2WT,RGD proteins conjugated via a peptide linker. N-TIMP2WT and N-TIMP25M are mono-specific binders for MMP-14. Ala-N-TIMP2WT,RGD has a reduced affinity toward MMP-14 and high affinity toward integrin avb3.

Related publications

Potent inhibition of MMP-9 by a novel sustained-release platform attenuates left ventricular remodeling following myocardial infarction

Itzhar A, Yosef G, Eilon-Ashkenazy M, Shmidov Y, Gil H, Lacham-Hartman S, Elyagon S, Etzion S, Bitton R, Cohen S, Etzion Y & Papo N. Journal of Controlled Release (JCR). 2023


Utilizing genetic code expansion to modify N-TIMP2 specificity towards MMP-2, MMP-9, and MMP-14.

 Hayun H, Coban M, Bhagat A.K. Radisky E. & Papo N. Scientific Reports.  2023.

Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy.

Yosef G, Hayun H, Papo N. Biochem J. 2021.


Targeting the MMP-14/MMP-2/integrin alpha(v)beta(3) axis with multispecific N-TIMP2-based antagonists for cancer therapy.

Yosef G, Arkadash V, Papo N. J Biol Chem. 2018.


A bi-specific inhibitor targeting IL-17A and MMP-9 reduces invasion and motility in MDA-MB-231 cells.

Koslawsky D, Zaretsky M, Alcalay R, Mazor O, Aharoni A, Papo N. Oncotarget. 2018.

Converting a broad matrix metalloproteinase family inhibitor into a specific inhibitor of MMP-9 and MMP-14.

Shirian J, Arkadash V, Cohen I, Sapir T, Radisky ES, Papo N, Shifman JM. FEBS Lett. 2018.


Development of High Affinity and High Specificity Inhibitors of Matrix Metalloproteinase 14 through Computational Design and Directed Evolution.

Arkadash V, Yosef G, Shirian J, Cohen I, Horev Y, Grossman M, Sagi I, Radisky ES, Shifman JM, Papo N. J Biol Chem. 2017.

bottom of page